NCT01525966View on ClinicalTrials.gov

Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

February 15, 2012

Primary Completion Date

January 11, 2019

Study Completion Date

December 8, 2025

Conditions
Inflammatory Breast CancerStage IIA Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerTriple-negative Breast CancerStage IIB Breast CancerEstrogen Receptor NegativeProgesterone Receptor NegativeHER2/Neu Negative
Interventions
DRUG

carboplatin

Given IV

DRUG

paclitaxel albumin-stabilized nanoparticle formulation

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (2)

91010

City of Hope Medical Center, Duarte

91030

City of Hope- South Pasadena Cancer Center, South Pasadena

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT01525966 - Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer | Biotech Hunter | Biotech Hunter